Roivant Sciences Ltd. (ROIV): Total Liabilities
$416.27M
As of 2026-03-31
$384.62M
As of 2026-06-30
-19.0%
3-year compound annual growth
-4.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $416.27M | +66.7% | 2026-05-20, Balance as of period end |
| 2025-03-31 | $249.74M | -67.7% | 2026-05-20, Balance as of period end |
| 2024-03-31 | $773.95M | -1.0% | 2025-05-29, Balance as of period end |
| 2023-03-31 | $782.02M | +49.3% | 2024-05-30, Balance as of period end |
| 2022-03-31 | $523.70M | -0.8% | 2023-06-28, Balance as of period end |
| 2021-03-31 | $527.69M | n/a | 2022-06-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $416.27M | +66.7% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $30.24M | -28.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $26.36M | -32.0% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $22.84M | -34.9% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $51.40M | +18.9% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.58M | -4.7% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
Compare ROIV, COYA, ACRS, BOLT side by side · Screen every company in Pharmaceutical Preparations ↗